Rosuvastatin (Crestor®);Rosuvastatine (Crestor®)

Revue Medicale de Liege

Volumn 59, Issue 1, 2004, Pages 56-59

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atherosclerosis; Cardiovascular disease; HMG CoA reductase inhibitor; Hypercholesterolaemia; Rosuvastatin; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; FLUOROBENZENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; DIET; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; BELGIUM; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; MORBIDITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BELGIUM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HUMANS; HYPERCHOLESTEROLEMIA; MORBIDITY; PATIENT SELECTION; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 1442328487     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Scheen AJ.- Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
2. Ducobu J, Scheen AJ.- Les recommandations du Belgian Lipid Club pour le diagnostic et le traitement des hyperlipidémies: résumé pour le praticien. Rev Med Liège, 2000, 55, 360-366.
3. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.- Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1600-1609.
4. Scheen AJ.- Les statines: du récepteur LDL à la protection cardio-vasculaire. Rev Med Liège, 1996, 51, 95-99.
5. Law MR, Wald NJ, Rudnicka AR.- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
6. Scheen AJ, Kulbertus H.- Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol ?. Rev Med Liège, 2003, 58, 191-197.
7. Bonetti PO, Lerman LO, Napoli C, Lerman A.- Statin effects beyond lipid lowering - are they clinically relevant ? Eur Heart J, 2003, 24, 225-248.
8. Scheen AJ, Lefèbvre PJ, Kulbertus H.- Comment je préviens ... Les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une "polypill"? Rev Med Liège, 2003, 58, 527-533.
9. Carswell CI, Plosker GL, Jarvis B.- Rosuvastatin. Drugs, 2002, 62, 2075-2085.
10. Schuster H.- Rosuvastatin - A highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology, 2003, 99, 126-139.
11. Olsson AG, Pears J, McKellar J, et al.- Effects of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol, 2001, 88, 504-508.
12. Paoletti R, Fahmy M, Mahla G, et al.- Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomised, double-blind study. J Cardiovasc Risk, 2001, 8, 383-390.
13. Brown WV, Bays HE, Hassman DR, et al.- Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J, 2002, 144, 1036-1043.
14. Olsson AG, Istad H, Luurila O, et al.- Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients ith hypercholesterolemia. Am Heart J, 2002, 144, 1044-1051.
15. Schneck DW, Knopp RH, Ballantyne CM, et al.- Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol, 2003, 91, 33-41.
16. Jones PH, Davidson MH, Stein EA, et al for the STELLAR Study Group.- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol, 2003, 92, 152-160.
17. Jacobson TA.- "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline ? Ann Intern Med, 2000, 133, 549-554.
18. Kennedy HL, Rosenson RS.- Physicians' interpretation of "class effects". A need for thoughtful re-evaluation. J Am Coll Cardiol, 2002, 40, 19-26.
19. Davidson MH.- Statin trials in progress: unanswered questions. Curr Atheroscler Rep, 2001, 3, 9-13.
20. Scheen AJ.- Pharmaco-économie des médicaments hypolipidémiants: analyse des facteurs influençant le rapport coût/efficacité. Rev Med Liège, 1998, 53, 220-222.